Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS Genet ; 11(8): e1005388, 2015 Aug.
Article in English | MEDLINE | ID: mdl-26247364

ABSTRACT

Calmodulin lysine methyl transferase (CaM KMT) is ubiquitously expressed and highly conserved from plants to vertebrates. CaM is frequently trimethylated at Lys-115, however, the role of CaM methylation in vertebrates has not been studied. CaM KMT was found to be homozygously deleted in the 2P21 deletion syndrome that includes 4 genes. These patients present with cystinuria, severe intellectual disabilities, hypotonia, mitochondrial disease and facial dysmorphism. Two siblings with deletion of three of the genes included in the 2P21 deletion syndrome presented with cystinuria, hypotonia, a mild/moderate mental retardation and a respiratory chain complex IV deficiency. To be able to attribute the functional significance of the methylation of CaM in the mouse and the contribution of CaM KMT to the clinical presentation of the 2p21deletion patients, we produced a mouse model lacking only CaM KMT with deletion borders as in the human 2p21deletion syndrome. No compensatory activity for CaM methylation was found. Impairment of complexes I and IV, and less significantly III, of the mitochondrial respiratory chain was more pronounced in the brain than in muscle. CaM KMT is essential for normal body growth and somatosensory development, as well as for the proper functioning of the adult mouse brain. Developmental delay was demonstrated for somatosensory function and for complex behavior, which involved both basal motor function and motivation. The mutant mice also had deficits in motor learning, complex coordination and learning of aversive stimuli. The mouse model contributes to the evaluation of the role of methylated CaM. CaM methylation appears to have a role in growth, muscle strength, somatosensory development and brain function. The current study has clinical implications for human patients. Patients presenting slow growth and muscle weakness that could result from a mitochondrial impairment and mental retardation should be considered for sequence analysis of the CaM KMT gene.


Subject(s)
Methyltransferases/physiology , Animals , Brain/enzymology , Brain/physiopathology , Chromosome Deletion , Feedback, Sensory , Female , Male , Methylation , Mice, 129 Strain , Mice, Inbred C57BL , Mice, Knockout , Muscle Strength , Muscle, Skeletal/enzymology , Muscle, Skeletal/pathology , Protein Processing, Post-Translational
2.
PLoS One ; 7(12): e52425, 2012.
Article in English | MEDLINE | ID: mdl-23285036

ABSTRACT

Deletion of the first exon of calmodulin-lysine N-methyltransferase (CaM KMT, previously C2orf34) has been reported in two multigene deletion syndromes, but additional studies on the gene have not been reported. Here we show that in the cells from 2p21 deletion patients the loss of CaM KMT expression results in accumulation of hypomethylated calmodulin compared to normal controls, suggesting that CaM KMT is essential for calmodulin methylation and there are no compensatory mechanisms for CaM methylation in humans. We have further studied the expression of this gene at the transcript and protein levels. We have identified 2 additional transcripts in cells of the 2p21 deletion syndrome patients that start from alternative exons positioned outside the deletion region. One of them starts in the 2(nd) known exon, the other in a novel exon. The transcript starting from the novel exon was also identified in a variety of tissues from normal individuals. These new transcripts are not expected to produce proteins. Immunofluorescent localization of tagged CaM KMT in HeLa cells indicates that it is present in both the cytoplasm and nucleus of cells whereas the short isoform is localized to the Golgi apparatus. Using Western blot analysis we show that the CaM KMT protein is broadly expressed in mouse tissues. Finally we demonstrate that the CaM KMT interacts with the middle portion of the Hsp90 molecular chaperon and is probably a client protein since it is degraded upon treatment of cells with the Hsp90 inhibitor geldanamycin. These findings suggest that the CaM KMT is the major, possibly the single, methyltransferase of calmodulin in human cells with a wide tissue distribution and is a novel Hsp90 client protein. Thus our data provides basic information for a gene potentially contributing to the patient phenotype of two contiguous gene deletion syndromes.


Subject(s)
Calmodulin/metabolism , HSP90 Heat-Shock Proteins/metabolism , Methyltransferases/metabolism , Amino Acid Sequence , Animals , Base Sequence , Benzoquinones/pharmacology , Cell Line , Chromosome Deletion , Chromosomes, Human, Pair 21/enzymology , Chromosomes, Human, Pair 21/genetics , Craniofacial Abnormalities/enzymology , Craniofacial Abnormalities/genetics , Cystinuria/enzymology , Cystinuria/genetics , Green Fluorescent Proteins/metabolism , HSP90 Heat-Shock Proteins/chemistry , Humans , Intellectual Disability/enzymology , Intellectual Disability/genetics , Lactams, Macrocyclic/pharmacology , Methylation/drug effects , Methyltransferases/chemistry , Methyltransferases/genetics , Mice , Mice, Inbred ICR , Mitochondrial Diseases/enzymology , Mitochondrial Diseases/genetics , Molecular Sequence Data , Muscle Hypotonia/enzymology , Muscle Hypotonia/genetics , Protein Binding/drug effects , Protein Stability/drug effects , Protein Structure, Tertiary , Protein Transport/drug effects , Proteolysis/drug effects , Recombinant Fusion Proteins/metabolism , Subcellular Fractions/drug effects , Subcellular Fractions/enzymology , Transcription, Genetic/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...